Peter Davies (1948 - 2020[1]) was a Welsh scientist and active researcher. He was the head and director of the Litwin-Zucker Research Center for The Study of Alzheimer's disease and memory disorders,[2] associated with the Feinstein Institute for Medical Research in Manhasset, New York, US.
Davies' research was focused on the biochemistry of Alzheimer's disease. His early work was in the development of the currently approved drugs for Alzheimer's disease: Aricept, Exelon and Razodyne. He was interested in the pathway of Alzheimer's disease, and said that the disease may be a process of uncontrolled cell cycle division. He had evidence that the switch that drives the cell cycle of neurons, which is a one-time event when the neuron is born, is somehow tripped and reactivated late in life. He and his team designed an experiment to turn on the cell cycle in laboratory models.[4] They put a viral oncogene into differentiated neurons and watched as pathological events progressed. In 2004 Davies and his collaborators identified a marker in cerebrospinal fluid (CSF) that can distinguish Alzheimer's disease from normal ageing, as well as discriminate between Alzheimer's and other forms of dementia.[5] The overall goal of Davies' research was to develop treatments to slow or halt the progression of Alzheimer's disease.
Awards and honors
International Congress on Alzheimer's Disease (ICAD) Lifetime Achievement Award[6]
Hampel H, Buerger K, Zinkowski R, Goernitz A, Teipel SJ, Andreasen N, Sjogren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Möller HJ, Davies P, Blennow K. "Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease – a comparative CSF study", Archives of General Psychiatry, 61; 95–102, 2004
Conrad C. Vianna C. Schultz C. Thal DR. Ghebremedhin E. Lenz J. Braak H. Davies P. "Molecular Evolution and Genetics of the Saitohin Gene and tau haplotype in Alzheimer's Disease and Argyrophilic Grain Disease". J Neurochem, 89, 179–188, 2004.
Bargorn S. Davies P. Mandelkow E. "Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain", Biochemistry43, 1694–1703, 2004.
Andorfer CA. Acker CM. Kress Y. Hof PR. Duff K. Davies P. "Cell Cycle Re-entry and Cell Death in Transgenic Mice Expressing Non-Mutant Human Tau Isoforms", J Neurosci25; 5446–5454, 2005.
Marambaud P. Zhao H. Davies P. "Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides", J Biol Chem280, 37377–37382, 2005.
de Leon MJ. DeSanti S. Zinkowski R. Mehta PD. Pratico D. Segala S. Rusinek H. Lia J. Tsui W. Saint Louis LA. Clark CM. Tarshish C. Lia Y. Lair L. Javier E. Rich K. Lesbre P. Mosconi L. Reisberg B. Sadowski M. DeBernadis JF. Kerkman DJ. Hampel H. Wahlund L-O. Davies P. "Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment", Neurobiology of Aging27, 394–401, 2006.
d’Abramo C. Ricciarelli R. Pronzato MA. Davies P. "Troglitazone, a Peroxisome Proliferator-activated Receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells", J. Neurochem98, 1068–1077, 2006.
Park KHJ. Hallows JL Chakrabarty P Davies P Vincent I. "Conditional neuronal SV40 T Antigen expression induces Alzheimer-like tau and amyloid pathology in mice", J Neurosci27, 2969–2978, 2007.
Espinoza M. de Silva R. Dickson DW. Davies P. "Differential Incorporation of Tau Isoforms in Alzheimer's Disease", Journal of Alzheimer’s Disease, 14, 1–16, 2008.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.